Published in Front Genet on February 04, 2015
Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol (2015) 1.02
Cationic Polyamidoamine Dendrimers as Modulators of EGFR Signaling In Vitro and In Vivo. PLoS One (2015) 0.78
Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer. Oncotarget (2016) 0.75
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer. Oncotarget (2016) 0.75
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell (1986) 7.06
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A (1992) 6.61
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature (1995) 5.51
The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer (2004) 5.47
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res (2002) 3.33
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell (2003) 3.20
The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res (2003) 3.18
Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res (1997) 3.18
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell (2009) 2.90
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett (2001) 2.86
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A (2010) 2.85
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature (2007) 2.78
Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell (1989) 2.74
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol (2014) 2.72
Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc Natl Acad Sci U S A (2007) 2.20
Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet (2014) 2.17
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res (2001) 2.06
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother (2005) 1.98
Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem (1999) 1.89
Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet (2011) 1.83
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog (2012) 1.75
Ligand-induced ErbB receptor dimerization. Exp Cell Res (2008) 1.73
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res (2005) 1.62
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol (2001) 1.56
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer (2007) 1.50
Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy. Cancer Sci (2012) 1.50
Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst (1988) 1.49
Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology (1997) 1.48
ErbB receptors and the development of the nervous system. Exp Cell Res (2008) 1.40
The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harb Perspect Biol (2014) 1.39
Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J Biol Chem (2009) 1.36
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res (2008) 1.34
Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein. Nature (1981) 1.31
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol (2007) 1.11
Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res (2007) 1.10
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res (2010) 1.10
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer (2007) 1.09
Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. BMC Evol Biol (2006) 1.06
The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol (2002) 1.03
Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. J Biol Chem (2007) 1.02
EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. J Cancer Res Clin Oncol (2008) 1.01
Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res (2004) 0.99
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res (2011) 0.98
Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. Cancer Epidemiol (2011) 0.94
A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk. Clin Cancer Res (2007) 0.93
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res (2014) 0.93
Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Cancer Genet Cytogenet (2006) 0.92
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer (2011) 0.92
Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer. Ann Oncol (2014) 0.89
Single Nucleotide Polymorphisms Associated with MicroRNA Regulation. Biomolecules (2013) 0.87
A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer (2003) 0.83
Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer. Pharmacoeconomics (2015) 0.81
Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer. BMC Cancer (2014) 0.81
ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer. PLoS One (2014) 0.76
Association between -276 C/T polymorphism of the ERBB3 gene and lung cancer risk in a Korean population. Anticancer Res (2012) 0.76